Methods for the treatment of COVID-19 comprising administering replication-defective adenoviruses encoding the SARS-CoV-2 spike glycoprotein and modified nucleocapsid protein
AssigneeNantCell, Inc.
InventorsKayvan Niazi, Thomas H. King
Life of this patent
Estimating the term…
Abstract
Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises comprises a recombinant entity. The recombinant entity comprises a nucleic acid that encodes a nucleocapsid protein of coronavirus 2 (CoV2); and/or wherein the recombinant entity encodes a spike protein of CoV2.
Claims12
A method for inducing immunity in an individual, the method comprising administration to the individual a replication defective adenoviral serotype-5 (Ad5) vector comprising 1) an E1 gene region deletion, 2) an E2b gene region deletion, 3) a nucleic acid sequence that encodes a SARS-COV-2 S protein having the amino acid sequence of SEQ ID NO:
- 4, and 4) a nucleic acid sequence that encodes a chimeric protein comprising a SARS-COV-2 N protein having the amino acid sequence of SEQ ID NO:
- 1 and an endosomal targeting sequence having the amino acid sequence of SEQ ID NO:
- 2.
A method for preventing and/or treating COVID-19 in an individual, the method comprising administration to the individual a replication defective adenoviral serotype-5 (Ad5) vector comprising 1) an E1 gene region deletion, 2) an E2b gene region deletion, 3) a nucleic acid sequence comprising a portion that encodes a SARS-COV-2 S protein having the amino acid sequence of SEQ ID NO:
- 4;
- and 4) a nucleic acid sequence that encodes a chimeric protein comprising a SARS-COV-2 N protein having the amino acid sequence of SEQ ID NO:
- 1, and an endosomal targeting sequence having the amino acid sequence of SEQ ID NO:
- 2.
Dependencies are inferred from the claim text.